Novo Nordisk A/S
NVO · NYSE
NVO · NYSE
Novo Nordisk is a Danish drugmaker focused on diabetes and obesity treatments, markets in which the evidence describes it as a giant and established leader. Its portfolio includes injectable GLP-1 medicines, while its pipeline contains additional GLP-1 candidates and the investigational therapy ziltivekimab. The company makes money by selling pharmaceutical treatments rather than through a disclosed non-pharmaceutical business. The supplied evidence identifies patients with diabetes, obesity and cardiovascular conditions as the relevant treatment populations, but does not provide a current revenue split by segment, customer breakdown, geographic mix or operating scale.
Novo Nordisk fell $6.68, or 13.11%, from $50.96 to $44.28 over the measured week. The main catalyst was disappointing ZEUS Phase 3 results: ziltivekimab showed success on the IL-6 pathway but failed to reduce cardiovascular events, prompting the sharpest decline on July 31, when shares dropped from $51.61 to $47.08 on 26.8 million shares and broke below the cited $47.00 200-day moving average. Selling intensified on August 4, with the stock losing another $2.81 to $44.28 on record-period volume of 47.5 million shares. Pre-Q2 uncertainty added pressure, as coverage cited slowing injectable GLP-1 momentum, pricing headwinds and competition. Broader market context was comparatively supportive, with the Nasdaq-100 pre-market indicator higher in the supplied observations.
LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance RaisedAMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug PressureNVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 GrowthPre-Market Most Active for Aug 5, 2026 : YXT, SPCX, MUU, SQQQ, CRCL, TSLL, TQQQ, NOK, UBER, FLUT, NVO, KO
